Page - (000405) - in Biomedical Chemistry: Current Trends and Developments

porous silicon/acetalated dextran nanocomposites for precisely controlled combination chemotherapy. Biomaterials, 39, 249-259. Liu, Q., Zhang, J., Sun, W., et al. (2012). Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells. International Journal of Nanomedicine, 7, 999-1013. Liu, R., Liao, P., Liu, J., et al. (2011). Responsive polymer-coated mesoporous silica as a ph- sensitive nanocarrier for controlled release. Langmuir, 27(6), 3095-3099. Liu, Y., Fang, J., Joo, K. I., (2014). Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor. PLoS One, 9(10), e110611. Livasy, C. A., Karaca, G., Nanda, R., et al. (2006). Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern Pathology, 19(2), 264-271. Lohr, J. M., Haas, S. L., Bechstein, W. O., et al. (2012). Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: A randomized controlled phase II trial. Annals of Oncology, 23(5), 1214-1222. Lowin, B., Peitsch, M. C., Tschopp, J. (1995). Perforin and granzymes: Crucial effector molecules in cytolytic t lymphocyte and natural killer cell-mediated cytotoxicity. Current Topics in Microbiology and Immunology, 198, 1-24. Ma, M., Zhang, Y., Gong, H., et al. (2013). Silica-coated magnetite nanoparticles labeled by nimotuzumab, a humanised monoclonal antibody to epidermal growth factor receptor: Preparations, specific targeting and bioimaging. Journal of Nanoscience and Nanotechnology, 13(10), 6541-6545. Ma, W., Chen, M., Kaushal, S., et al. (2012). Plga nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. International Journal of Nanomedicine, 7, 1475-1487. Ma, Y., Zheng, Y., Zeng, X., et al. (2011). Novel docetaxel-loaded nanoparticles based on pcl- tween 80 copolymer for cancer treatment. International Journal of Nanomedicine, 6, 2679- 2688. MacEwan, S. R., Callahan, D. J., Chilkoti, A. (2010). Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine (Lond), 5(5), 793-806. Maeda, H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation, 41, 189-207. Maeda, H., Wu, J., Sawa, T., et al. (2000). Tumor vascular permeability and the epr effect in macromolecular therapeutics: A review. Journal of Controlled Release, 65(1-2), 271-284. Mäkilä, E., Ferreira, M. P., Kivela, H., et al. (2014). Confinement effects on drugs in thermally hydrocarbonized porous silicon. Langmuir, 30(8), 2196-2205. Mallapragada, S. K., Narasimhan, B. (2008). Immunomodulatory biomaterials. International Journal of Pharmaceutics, 364(2), 265-271. Manolova, V., Flace, A., Bauer, M., et al. (2008). Nanoparticles target distinct dendritic cell populations according to their size. European Journal of Immunology, 38(5), 1404-1413. Mansour, A. M., Drevs, J., Esser, N., et al. (2003). A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Research, 63(14), 4062-4066. Markman, J. L., Rekechenetskiy, A., Holler, E., et al. (2013). Nanomedicine therapeutic